Evaluation system for intervening HPV infection treatment by using 5-fluorouracil

Abstract

The invention belongs to the technical field of HPV (human papillomavirus) infection treatment, and particularly relates to an evaluation system for intervening HPV infection treatment by using 5-fluorouracil, which comprises a sample collection module, an infection state evaluation module, a first monitoring module, a second monitoring module and a curative effect evaluation module. According to the present invention, the biological sample of the HPV infected person is quantitatively detected, such that the 5-fluorouracil intervention treatment effect can be accurately evaluated, the optimal dose can be determined according to the comprehensive score so as to improve the treatment pertinence and the treatment efficiency, and the adverse reaction can be timely found and early warned by monitoring the 5-fluorouracil blood concentration in real time so as to provide the good treatment effect. And through real-time monitoring and comprehensive scoring, doctors can adjust the medicine dosage according to individual differences of patients, and personalized treatment is achieved. Meanwhile, due to the introduction of the early warning module, additional safety guarantee is provided for clinical treatment, and side effects of drugs and adverse events can be reduced.

Description

Technical Field

[0001] The present invention belongs to the technical field of HPV infection treatment, and in particular relates to an evaluation system for HPV infection treatment intervention using 5-fluorouracil. Background Art

[0002] As persistent infection with high-risk human papillomavirus (HPV) is the most direct cause of cervical intraepithelial neoplasia and cervical cancer, the correlation between the two reaches 95%-98%. Completely blocking the transcription of HPV infection and clearing HPV-infected cells are considered to be the key to treating diseases caused by HPV. At this stage, there is a lack of antiviral drugs that directly target the HPV virus itself, especially in terms of long-term effects of completely clearing the virus and preventing HPV-related cancers. Fluorouracil (5-FU) is an anti-metabolite. After entering the human body, it is converted into 5-fluorouracil deoxynucleotides, covalently binds to the active center of thymidylate synthase, blocks the conversion of deoxynucleotides to thymine nucleotides, and inhibits DNA synthesis. In addition, its metabolites can also be incorporated into DNA and RNA in the form of pseudo-metabolites, which have certain cytotoxicity and can promote cell necrosis and apoptosis in a short period of time.

[0003] In the prior art, there is a difficulty in controlling the dosage of 5-fluorouracil (5-FU) in clinical applications. Due to its narrow therapeutic window, insufficient dosage cannot achieve the expected antiviral effect, while excessive dosage may cause serious adverse reactions. Therefore, how to accurately evaluate the therapeutic effect of 5-FU on HPV infection and determine the optimal dosage range is the key to improving the therapeutic effect and reducing adverse reactions. In order to solve the above problems, the present invention proposes an evaluation system for the use of 5-fluorouracil to intervene in the treatment of HPV infection. Summary of the invention

[0004] The purpose of the present invention is to provide an evaluation system for the use of 5-fluorouracil to intervene in the treatment of HPV infection, which can evaluate the therapeutic effect of 5-fluorouracil (5-FU) on HPV infection and determine the optimal dosage range to improve the therapeutic effect and reduce adverse reactions.

[0005] The technical solution adopted by the present invention is as follows: An evaluation system for using 5-fluorouracil to intervene in the treatment of HPV infection, comprising a sample collection module, an infection status evaluation module, a first monitoring module, a second monitoring module and an efficacy evaluation module; The sample collection module is used to collect biological samples from HPV infected people, and the biological samples include blood, saliva and cervical secretions; The infection status evaluation module is used to collect the viral load of the biological sample and the HPV DNA content in the biological sample, and determine the infection degree of the biological sample according to the viral load and the HPV DNA content; The first monitoring module is used to monitor the changes in DNA levels in HPV-infected tissues under the intervention of 5-fluorouracil, and record them as the first monitoring parameter; The second monitoring module is used to monitor the changes in HPV transcription activity under the intervention of 5-fluorouracil and record it as the second monitoring parameter; The efficacy evaluation module is used to comprehensively evaluate the therapeutic effect of 5-fluorouracil on HPV infection by combining the first monitoring parameter and the second monitoring parameter, and simultaneously output a comprehensive score, and then determine the optimal dose of 5-fluorouracil based on the comprehensive score.

[0006] In a preferred embodiment, the sample collection module includes a sample collection unit and a sample processing unit. The sample collection unit is used to collect biological samples from HPV-infected persons, and the sample processing unit is used to pre-treat the collected biological samples, wherein the pre-treatment includes centrifugation, labeling and packaging.

[0007] In a preferred embodiment, the infection status evaluation module includes a detection unit and a status evaluation unit, wherein the detection unit is used to detect the HPV DNA content in the biological sample and to measure the viral load in the biological sample; The state evaluation unit is preset with a first evaluation interval for comparison with the HPV DNA content and a second evaluation interval for comparison with the viral load, and both the first evaluation interval and the second evaluation interval correspond to multiple infection levels; Wherein, after the HPV DNA content and viral load of the biological sample output by the detection unit are output, they are compared with the first evaluation interval and the second evaluation interval respectively to determine the infection level of the biological sample; When the infection levels outputted in the first evaluation interval and the second evaluation interval are consistent, the infection levels outputted in the first evaluation interval and the second evaluation interval are directly used as the infection degree of the biological sample; When the infection levels outputted in the first evaluation interval and the second evaluation interval are inconsistent, the higher infection level is used as the infection degree of the biological sample.

[0008] In a preferred embodiment, the first monitoring module includes a real-time PCR detection unit and a first recording unit, and the real-time PCR detection unit is used to perform quantitative PCR detection on HPV-infected tissue after 5-fluorouracil intervention; The first recording unit is used to record the HPV DNA level change data obtained by the real-time PCR detection unit, and calibrate the HPV DNA level change data as the first monitoring parameter for recording.

[0009] In a preferred embodiment, the second monitoring module includes a reverse transcription PCR detection unit and a second recording unit, wherein the reverse transcription PCR detection unit is used to perform quantitative reverse transcription PCR detection on HPV-infected tissues after 5-fluorouracil intervention to monitor changes in HPV transcription activity; The second recording unit is used to record the HPV transcription activity change data obtained by the reverse transcription PCR detection unit, and mark the HPV transcription activity change data as a second monitoring parameter for recording.

[0010] In a preferred solution, after the first monitoring parameter and the second monitoring parameter are output, the first monitoring parameter and the second monitoring parameter are arranged according to the occurrence time sequence; Bidirectionally offsetting the arranged first monitoring parameters and second monitoring parameters respectively to obtain a plurality of first monitoring intervals corresponding to the first monitoring parameters and a plurality of second monitoring intervals corresponding to the second monitoring parameters; Collecting the number of first monitoring parameters in each of the first monitoring intervals and marking them as first parameters to be screened, and collecting the number of second monitoring parameters in each of the second monitoring intervals and marking them as second parameters to be screened; Obtaining a screening threshold, and comparing the screening threshold with the first parameter to be screened and the second parameter to be screened, and recording a first monitoring interval under the first parameter to be screened that is greater than the screening threshold as a first standard interval, and recording a second monitoring interval under the second parameter to be screened that is greater than the screening threshold as a second standard interval; The first monitoring parameter within the first standard interval and the second monitoring parameter within the second standard interval are retained, and the first monitoring parameter outside the first standard interval and the second monitoring parameter outside the second standard interval are screened out.

[0011] In a preferred embodiment, the efficacy evaluation module includes a comprehensive scoring unit and a dosage optimization unit, wherein the comprehensive scoring unit is provided with a comprehensive evaluation function, and the comprehensive evaluation function is used to calculate a comprehensive score of the treatment effect of HPV infection by comprehensively combining the first monitoring parameter and the second monitoring parameter, as well as the weight coefficient of the first monitoring parameter and the second monitoring parameter; The dose optimization unit is used to collect the intervention dose of 5-fluorouracil of biological samples with the same infection degree under each of the comprehensive scores, and determine the correlation formula between the intervention dose and the comprehensive score, and then determine the optimal dose of 5-fluorouracil intervention based on the correlation formula.

[0012] In a preferred embodiment, it further comprises an early warning module, which is used to monitor adverse reactions of biological samples in the 5-fluorouracil intervention process in real time and send out an early warning signal when an adverse reaction is detected; The early warning module includes a real-time monitoring unit and an early warning determination unit, wherein the real-time monitoring unit is used to monitor the blood concentration of 5-fluorouracil in the biological sample; The early warning determination unit analyzes the blood drug concentration according to a preset allowable fluctuation range, and when it is detected that the blood drug concentration exceeds the allowable fluctuation range, the early warning mechanism is triggered to send out an early warning signal.

[0013] The present invention also provides an evaluation method for the use of 5-fluorouracil to intervene in the treatment of HPV infection, which is applied to the above-mentioned evaluation system for the use of 5-fluorouracil to intervene in the treatment of HPV infection, comprising: Collecting biological samples from HPV-infected persons, wherein the biological samples include blood, saliva, and cervical secretions; Collecting the viral load of the biological sample and the HPV DNA content in the biological sample, and determining the infection degree of the biological sample based on the viral load and the HPV DNA content; Monitor the changes in DNA levels in HPV-infected tissues under 5-fluorouracil intervention and record them as the first monitoring parameter; Monitor the changes in HPV transcription activity under the intervention of 5-fluorouracil and record it as the second monitoring parameter; The first monitoring parameter and the second monitoring parameter are combined to evaluate the therapeutic effect of 5-fluorouracil in intervening HPV infection, and a comprehensive score is output simultaneously, and then the optimal dose of 5-fluorouracil is determined based on the comprehensive score.

[0014] And, an electronic device, the electronic device comprising: at least one processor; and a memory communicatively coupled to the at least one processor; Wherein, the memory stores a computer program executable by the at least one processor, and the computer program is executed by the at least one processor so that the at least one processor can execute the above-mentioned evaluation system for using 5-fluorouracil to intervene in the treatment of HPV infection.

[0015] The technical effects achieved by the present invention are: The present invention can accurately evaluate the effect of 5-fluorouracil intervention therapy by quantitatively detecting biological samples of HPV-infected persons, and can determine the optimal dose according to the comprehensive score, thereby improving the pertinence and efficiency of the treatment. In addition, by real-time monitoring of the blood concentration of 5-fluorouracil, adverse reactions can be discovered and warned in time to ensure the safety of treatment. Through real-time monitoring and comprehensive scoring, doctors can adjust the drug dose according to individual differences of patients to achieve personalized treatment. At the same time, the introduction of the early warning module provides additional safety protection for clinical treatment and helps reduce the occurrence of drug side effects and adverse events. BRIEF DESCRIPTION OF THE DRAWINGS

[0016] Figure 1 It is a schematic diagram of the system module of the present invention; Figure 2 It is a schematic flow chart of the method of the present invention; Figure 3 It is a schematic diagram of the structure of an electronic device of the present invention. DETAILED DESCRIPTION

[0017] In order to make the above-mentioned objects, features and advantages of the present invention more obvious and easy to understand, the specific implementation methods of the present invention are described in detail below in conjunction with the accompanying drawings.

[0018] In the following description, many specific details are set forth to facilitate a full understanding of the present invention, but the present invention may also be implemented in other ways different from those described herein, and those skilled in the art may make similar generalizations without violating the connotation of the present invention. Therefore, the present invention is not limited to the specific embodiments disclosed below.

[0019] Secondly, the term "one embodiment" or "embodiment" as used herein refers to a specific feature, structure or characteristic that may be included in at least one implementation of the present invention. The phrase "in a preferred embodiment" that appears in different places in this specification does not refer to the same embodiment, nor is it a separate or selective embodiment that is mutually exclusive with other embodiments.

[0020] See also Figure 1 As shown, the present invention provides an evaluation system for using 5-fluorouracil to intervene in the treatment of HPV infection, including a sample collection module, an infection status evaluation module, a first monitoring module, a second monitoring module and an efficacy evaluation module; The sample collection module is used to collect biological samples from HPV-infected people, including blood, saliva, and cervical secretions; The infection status evaluation module is used to collect the viral load of the biological sample and the HPV DNA content in the biological sample, and determine the infection degree of the biological sample based on the viral load and the HPV DNA content; The first monitoring module is used to monitor the changes in the DNA level of HPV-infected tissues under the intervention of 5-fluorouracil and record it as the first monitoring parameter; The second monitoring module is used to monitor the changes in HPV transcription activity under the intervention of 5-fluorouracil and record it as the second monitoring parameter; The efficacy evaluation module is used to comprehensively evaluate the therapeutic effect of 5-fluorouracil on HPV infection by combining the first monitoring parameter and the second monitoring parameter, and simultaneously output a comprehensive score, and then determine the optimal dose of 5-fluorouracil based on the comprehensive score.

[0021] As mentioned above, with the deepening of research on the treatment of HPV infection, 5-fluorouracil, as an effective antiviral drug, has shown significant therapeutic effects in clinical applications. However, how to accurately evaluate the therapeutic effect of 5-fluorouracil on HPV infection and determine the optimal dose has always been a difficulty in clinical research. The evaluation system provided in this embodiment is composed of a sample collection module, an infection status evaluation module, a first monitoring module, a second monitoring module and an efficacy evaluation module. The sample collection module is mainly responsible for collecting biological samples from HPV-infected people. The biological samples can be blood, saliva or cervical secretions. The infection status evaluation module is responsible for analyzing the collected biological samples. Specifically, it will measure the viral load and HPV in the sample. The DNA content can accurately assess the infection degree of biological samples. The first monitoring module is responsible for monitoring the changes in DNA levels of HPV-infected tissues under the intervention of 5-fluorouracil, and recording the changes in DNA levels of HPV-infected tissues as the first monitoring parameter. The second monitoring module focuses on the changes in HPV transcriptional activity under the intervention of 5-fluorouracil, and records the changes in HPV transcriptional activity as the second monitoring parameter, providing a preliminary data reference for subsequent efficacy evaluation. The efficacy evaluation module will comprehensively evaluate the therapeutic effect of 5-fluorouracil intervention for HPV infection based on the first monitoring parameter and the second monitoring parameter, and will output a comprehensive score to quantify the treatment effect. Finally, the optimal dose of 5-fluorouracil will be determined based on the comprehensive score, thereby providing a scientific basis for clinical treatment.

[0022] In a preferred embodiment, the sample collection module includes a sample collection unit and a sample processing unit. The sample collection unit is used to collect biological samples from HPV-infected persons, and the sample processing unit is used to pre-treat the collected biological samples, and the pre-treatment includes centrifugation, labeling and packaging.

[0023] In this embodiment, the sample collection module is mainly composed of two parts: a sample collection unit and a sample processing unit. The main responsibility of the sample collection unit is to obtain the required biological samples from HPV (human papillomavirus) infected persons. The biological samples may include blood, saliva, urine or other body fluids, depending on the needs of the research or detection. The collection process needs to be carried out strictly in accordance with the aseptic operating procedures to ensure the purity and integrity of the samples. The sample processing unit is responsible for the task of performing preliminary processing on the collected biological samples to ensure that the samples meet the required quality standards before further analysis. First, the biological samples will be centrifuged to separate the cellular components and liquid components for subsequent operations. Then the biological samples will be labeled to ensure the traceability of the biological samples during the processing and analysis process to prevent confusion or errors in the biological samples. Finally, the biological samples will be divided into different containers for different tests or storage to ensure the accuracy and reliability of the experimental data finally obtained.

[0024] In a preferred embodiment, the infection status evaluation module includes a detection unit and a status evaluation unit, the detection unit is used to detect the HPV DNA content in the biological sample and to measure the viral load in the biological sample; The state evaluation unit is preset with a first evaluation interval for comparison with HPV DNA content and a second evaluation interval for comparison with viral load, and both the first evaluation interval and the second evaluation interval correspond to multiple infection levels; Among them, after the HPV DNA content and viral load of the biological sample output by the detection unit are output, they are compared with the first evaluation interval and the second evaluation interval respectively to determine the infection level of the biological sample; When the infection levels outputted in the first evaluation interval and the second evaluation interval are consistent, the infection levels outputted in the first evaluation interval and the second evaluation interval are directly used as the infection degree of the biological sample; When the infection levels outputted in the first evaluation interval and the second evaluation interval are inconsistent, the higher infection level is used as the infection degree of the biological sample.

[0025] In the above, the infection status evaluation module is composed of a detection unit and a status evaluation unit. The detection unit is used to detect the HPV DNA content in the biological sample and measure the viral load in the biological sample to ensure that the data of the HPV DNA content and the viral load can be accurately obtained. The status evaluation unit has a built-in first evaluation interval for comparison with the HPV DNA content and a second evaluation interval for comparison with the viral load. The first evaluation interval and the second evaluation interval correspond to multiple different infection levels, respectively, so that the infection status of the biological sample can be evaluated more carefully. The first evaluation interval and the second evaluation interval are designed to provide a standardized reference framework to facilitate the comparison and analysis of the HPV DNA content and viral load data output by the detection unit. After the detection unit outputs the HPV DNA content and viral load of the biological sample, the infection level of the biological sample can be determined by comparing with the first evaluation interval and the second evaluation interval. If the infection levels output by the first evaluation interval and the second evaluation interval are consistent during the comparison process, then the infection levels output by the two evaluation intervals can be directly used as the infection level of the biological sample. However, if the infection levels output by the first evaluation interval and the second evaluation interval are inconsistent, the status evaluation unit will use the result with the higher infection level as the infection level of the biological sample. This approach is to ensure that a more conservative and safe evaluation result can be provided in the face of uncertainty, thereby avoiding underestimating the infection risk of the sample.

[0026] In a preferred embodiment, the first monitoring module includes a real-time PCR detection unit and a first recording unit, and the real-time PCR detection unit is used to perform quantitative PCR detection on HPV-infected tissue after 5-fluorouracil intervention; The first recording unit is used to record the HPV DNA level change data obtained by the real-time PCR detection unit, and calibrate the HPV DNA level change data as the first monitoring parameter for recording.

[0027] In this embodiment, the first monitoring module is composed of a real-time PCR detection unit and a first recording unit. The main function of the real-time PCR detection unit is to perform corresponding quantitative PCR detection on HPV-infected tissue samples after 5-fluorouracil drug intervention treatment, so as to monitor and quantify the HPV DNA content in the sample in real time. Specifically, the hybridization capture technology is used to quantitatively analyze the HPV-DNA load before and after treatment, aiming to clarify the direct impact of 5-FU local treatment on the HPV infection status, thereby providing reliable data support for subsequent analysis. At the same time, the first recording unit will record the monitored HPV DNA level change data to ensure the accuracy of the HPV DNA level change data. In addition, the first recording unit will further process and calibrate the HPV DNA level change data, and convert it into the first monitoring parameter for subsequent analysis and evaluation.

[0028] In a preferred embodiment, the second monitoring module includes a reverse transcription PCR detection unit and a second recording unit, and the reverse transcription PCR detection unit is used to perform quantitative reverse transcription PCR detection on HPV-infected tissue after 5-fluorouracil intervention to monitor changes in HPV transcription activity; The second recording unit is used to record the HPV transcription activity change data obtained by the reverse transcription PCR detection unit, and mark the HPV transcription activity change data as the second monitoring parameter for recording.

[0029] In this embodiment, the second monitoring module is mainly composed of a reverse transcription PCR detection unit and a second recording unit. The main function of the reverse transcription PCR detection unit is to perform quantitative reverse transcription PCR detection on HPV-infected tissues after treatment with 5-fluorouracil to monitor whether the transcriptional activity of HPV has changed. By adopting qRT-PCR technology to monitor the RNA expression level of HPV during treatment, it will help to clarify the mechanism of 5-FU's intervention in the HPV life cycle at the molecular level, thereby providing a basis for molecular targeted therapy for HPV-related diseases. In this way, the effect of 5-fluorouracil on HPV-infected tissues can be accurately evaluated. The second recording unit is responsible for recording the HPV transcriptional activity change data obtained by the reverse transcription PCR detection unit. After processing and analysis, the HPV transcriptional activity change data will be calibrated as the second monitoring parameter and recorded, providing important data support for subsequent research and treatment.

[0030] In a preferred embodiment, after the first monitoring parameter and the second monitoring parameter are output, the first monitoring parameter and the second monitoring parameter are arranged according to the time sequence of occurrence; Bidirectionally offsetting the arranged first monitoring parameters and second monitoring parameters respectively to obtain a plurality of first monitoring intervals corresponding to the first monitoring parameters and a plurality of second monitoring intervals corresponding to the second monitoring parameters; Collecting the number of first monitoring parameters in each first monitoring interval and marking them as first parameters to be screened, collecting the number of second monitoring parameters in each second monitoring interval and marking them as second parameters to be screened; Obtain a screening threshold, and compare the screening threshold with the first parameter to be screened and the second parameter to be screened, and record the first monitoring interval under the first parameter to be screened greater than the screening threshold as the first standard interval, and record the second monitoring interval under the second parameter to be screened greater than the screening threshold as the second standard interval; The first monitoring parameter within the first standard interval and the second monitoring parameter within the second standard interval are retained, and the first monitoring parameter outside the first standard interval and the second monitoring parameter outside the second standard interval are screened out.

[0031] In the above, after the first monitoring parameter and the second monitoring parameter are output, the first monitoring parameter and the second monitoring parameter will be arranged in the order of their occurrence. After the arrangement is completed, the arranged first monitoring parameter and the second monitoring parameter will be subjected to bidirectional offset processing respectively. Based on this, multiple first monitoring intervals corresponding to the first monitoring parameter and multiple second monitoring intervals corresponding to the second monitoring parameter can be obtained. Then, the number of first monitoring parameters in each first monitoring interval will be counted, and the number of first monitoring parameters will be used as the first parameter to be screened. Similarly, the number of second monitoring parameters in each second monitoring interval will also be counted, and the number of second monitoring parameters will be recorded as the second parameter to be screened. The purpose is to determine which parameters are valid. By introducing a preset screening threshold and comparing it with the first parameter to be screened and the second parameter to be screened, the first monitoring interval in which the first parameter to be screened is greater than the screening threshold can be identified and recorded as the first standard interval. Similarly, the second monitoring interval in which the second parameter to be screened is greater than the screening threshold will also be identified and recorded as the second standard interval. Finally, those first monitoring parameters belonging to the first standard interval and those first monitoring parameters belonging to the second standard interval will be retained. At the same time, we will screen out the first monitoring parameters that do not belong to the first standard interval and the second monitoring parameters that belong to the second standard interval. In this way, we can ensure that the data finally retained are valid data that meet the screening criteria. For example, if the screening threshold is set to 80%, then among all the first monitoring parameters, the data within the first monitoring interval that is greater than 80% will be retained, and the first monitoring parameters within the first monitoring interval that is less than 80% will be excluded. This can ensure the accuracy and reliability of the data and avoid the introduction of unnecessary noise and errors.

[0032] In a preferred embodiment, the efficacy evaluation module includes a comprehensive scoring unit and a dose optimization unit, wherein a comprehensive evaluation function is provided in the comprehensive scoring unit, and the comprehensive evaluation function is used to comprehensively calculate the comprehensive score of the treatment effect of HPV infection by combining the first monitoring parameter and the second monitoring parameter, as well as the weight coefficient of the first monitoring parameter and the second monitoring parameter; The dose optimization unit is used to collect the intervention dose of 5-fluorouracil for biological samples with the same degree of infection under various comprehensive scores, determine the correlation formula between the intervention dose and the comprehensive score, and then determine the optimal dose of 5-fluorouracil intervention based on the correlation formula.

[0033] In this implementation, the efficacy evaluation module is composed of a comprehensive scoring unit and a dose optimization unit. In the comprehensive scoring unit, a comprehensive evaluation function is set to comprehensively analyze and evaluate the first monitoring parameter and the second monitoring parameter. Specifically, it will comprehensively consider the first monitoring parameter and the second monitoring parameter, and will calculate the comprehensive score of the HPV infection treatment effect according to the weight coefficient of the first monitoring parameter and the second monitoring parameter, so as to provide a quantitative reference for doctors to help them more accurately evaluate the treatment effect. The expression of the comprehensive evaluation function is: , where represents the weight coefficient of the first monitoring parameter, The weight coefficient of the second monitoring parameter is determined by the clinical feedback data and the doctor's experience. Indicates the comprehensive rating. represents the number of the first monitoring parameter, represents the first monitoring parameter, represents the second monitoring parameter, represents the number of the second monitoring parameters. The dose optimization unit is responsible for collecting the intervention doses of 5-fluorouracil received by biological samples with the same infection degree under different comprehensive scores, and determining the correlation between the intervention dose and the comprehensive score based on multiple groups of corresponding intervention doses and comprehensive scores. The correlation between the intervention dose and the comprehensive score is a unimodal function ( ), Indicates the comprehensive rating. represents the intervention dose, , , are all constants. Through this correlation formula, the optimal dose of 5-fluorouracil intervention can be determined. Of course, this optimal dose may still have slight deviations, but in practical applications, it can provide corresponding data support for doctors to adjust the intervention dose of 5-fluorouracil, which not only improves the accuracy of treatment, but also reduces drug waste and the risk of side effects, ensuring that patients can obtain better treatment effects.

[0034] In a preferred embodiment, the system further comprises an early warning module, which is used to monitor adverse reactions of biological samples in the 5-fluorouracil intervention process in real time and issue an early warning signal when an adverse reaction is detected; The early warning module includes a real-time monitoring unit and an early warning determination unit. The real-time monitoring unit is used to monitor the blood concentration of 5-fluorouracil in the biological sample; The early warning determination unit analyzes the blood drug concentration according to a preset allowable fluctuation range, and when it is detected that the blood drug concentration exceeds the allowable fluctuation range, the early warning mechanism is triggered to send out an early warning signal.

[0035] In this embodiment, the function of the early warning module is to detect possible adverse reactions of biological samples during the treatment with 5-fluorouracil. Once any adverse reaction is found, the early warning module will immediately issue a warning signal so that relevant personnel can take corresponding measures in time. The early warning module includes a real-time monitoring unit and an early warning judgment unit. The real-time monitoring unit is responsible for continuously tracking and recording the blood concentration of 5-fluorouracil in the biological sample to ensure that the drug concentration remains within a safe and effective range. The early warning judgment unit analyzes the blood concentration data collected by the real-time monitoring unit according to a pre-set allowable fluctuation range. If the analysis result shows that the patient's blood drug concentration exceeds the allowable fluctuation range, the early warning judgment unit will immediately trigger the early warning mechanism and issue a warning signal. The warning signal can be transmitted to medical staff visually, auditorily or through other communication methods so that they can take quick measures to prevent the adverse reaction from further deteriorating.

[0036] See also Figure 2 , an evaluation method for the use of 5-fluorouracil to intervene in the treatment of HPV infection, applied to the above-mentioned evaluation system for the use of 5-fluorouracil to intervene in the treatment of HPV infection, comprising: Collect biological samples from people infected with HPV, including blood, saliva, and cervical secretions; Collecting the viral load of the biological sample and the HPV DNA content in the biological sample, and determining the infection degree of the biological sample based on the viral load and the HPV DNA content; Monitor the changes in DNA levels in HPV-infected tissues under 5-fluorouracil intervention and record them as the first monitoring parameter; Monitor the changes in HPV transcription activity under the intervention of 5-fluorouracil and record it as the second monitoring parameter; The first monitoring parameter and the second monitoring parameter are combined to evaluate the therapeutic effect of 5-fluorouracil in intervening HPV infection, and a comprehensive score is output simultaneously. The optimal dose of 5-fluorouracil is then determined based on the comprehensive score.

[0037] In the above, when evaluating the intervention treatment of HPV infection with 5-fluorouracil, a biological sample is first collected from the HPV-infected person. The biological sample can be blood, saliva or cervical secretions, and then the viral load of the biological sample is measured, and the HPV DNA content in the sample is detected. By analyzing the data of viral load and HPV DNA content, the infection degree of the biological sample can be evaluated. Under the intervention of 5-fluorouracil, the DNA level of HPV-infected tissue is continuously monitored, and the change data of the DNA level of HPV-infected tissue is recorded as the first monitoring parameter. At the same time, the change data of HPV transcriptional activity needs to be monitored and recorded as the second monitoring parameter. The first monitoring parameter and the second monitoring parameter are then comprehensively analyzed to evaluate the therapeutic effect of 5-fluorouracil intervention on HPV infection. Through comprehensive evaluation, a comprehensive score can be obtained. The comprehensive score can reflect the therapeutic effect of 5-fluorouracil. According to the result of the comprehensive score, the optimal dose of 5-fluorouracil can be further determined, thereby providing corresponding data support for clinical treatment.

[0038] See also Figure 3 , an electronic device, the electronic device comprising: at least one processor; and a memory communicatively coupled to the at least one processor; The memory stores a computer program executable by at least one processor, and the computer program is executed by at least one processor so that the at least one processor can execute the above-mentioned evaluation system for using 5-fluorouracil to intervene in the treatment of HPV infection.

[0039] In the above, the electronic device can be various types of computers, servers, smart phones, tablet computers or other programmable devices. The processor of the electronic device can be a central processing unit (CPU), a graphics processing unit (GPU) or other types of microprocessors. The memory can include random access memory (RAM), read-only memory (ROM), solid-state drive (SSD) or other forms of storage media. Computer programs can be stored in the memory in the form of software, firmware or microcode, and the electronic device also includes input and output devices and an operator to support the processor to perform various tasks. The input and output devices can include a keyboard, a mouse, a touch screen, a display, a printer, etc., which are used to receive user input and display processing results. The operator is responsible for performing specific mathematical and logical operations to ensure that the electronic device can process data efficiently.

[0040] It should be noted that, in this article, the terms "include", "comprises" or any other variations thereof are intended to cover non-exclusive inclusion, so that a process, device, article or method including a series of elements includes not only those elements, but also includes other elements not explicitly listed, or also includes elements inherent to such process, device, article or method. In the absence of further restrictions, an element defined by the sentence "includes a ..." does not exclude the presence of other identical elements in the process, device, article or method including the element.

[0041] The above is only a preferred embodiment of the present invention. It should be noted that, for those skilled in the art, several improvements and modifications can be made without departing from the principles of the present invention, and these improvements and modifications should also be considered as the protection scope of the present invention. The structures, devices and operating methods not specifically described and explained in the present invention shall be implemented according to the conventional means in the art unless otherwise specified and limited.

Claims

1. An evaluation system for the treatment of HPV infection using 5-fluorouracil, characterized in that: It includes a sample collection module, an infection status evaluation module, a first monitoring module, a second monitoring module and an efficacy evaluation module; The sample collection module is used to collect biological samples from HPV infected people, and the biological samples include blood, saliva and cervical secretions; The infection status evaluation module is used to collect the viral load of the biological sample and the HPV DNA content in the biological sample, and determine the infection degree of the biological sample according to the viral load and the HPV DNA content; The first monitoring module is used to monitor the changes in DNA levels in HPV-infected tissues under the intervention of 5-fluorouracil, and record them as the first monitoring parameter; The second monitoring module is used to monitor the changes in HPV transcription activity under the intervention of 5-fluorouracil and record it as the second monitoring parameter; The efficacy evaluation module is used to comprehensively evaluate the therapeutic effect of 5-fluorouracil on HPV infection by combining the first monitoring parameter and the second monitoring parameter, and simultaneously output a comprehensive score, and then determine the optimal dose of 5-fluorouracil based on the comprehensive score.

2. The evaluation system for the treatment of HPV infection using 5-fluorouracil according to claim 1, characterized in that: The sample collection module includes a sample collection unit and a sample processing unit. The sample collection unit is used to collect biological samples from HPV-infected persons. The sample processing unit is used to pre-process the collected biological samples. The pre-processing includes centrifugation, labeling and packaging.

3. The evaluation system for the treatment of HPV infection using 5-fluorouracil according to claim 1, characterized in that: The infection status evaluation module includes a detection unit and a status evaluation unit, wherein the detection unit is used to detect the HPV DNA content in the biological sample and to measure the viral load in the biological sample; The state evaluation unit is preset with a first evaluation interval for comparison with the HPV DNA content and a second evaluation interval for comparison with the viral load, and both the first evaluation interval and the second evaluation interval correspond to multiple infection levels; Wherein, after the HPV DNA content and viral load of the biological sample output by the detection unit are output, they are compared with the first evaluation interval and the second evaluation interval respectively to determine the infection level of the biological sample; When the infection levels outputted in the first evaluation interval and the second evaluation interval are consistent, the infection levels outputted in the first evaluation interval and the second evaluation interval are directly used as the infection degree of the biological sample; When the infection levels outputted in the first evaluation interval and the second evaluation interval are inconsistent, the higher infection level is used as the infection degree of the biological sample.

4. The evaluation system for the treatment of HPV infection using 5-fluorouracil according to claim 1, characterized in that: The first monitoring module includes a real-time PCR detection unit and a first recording unit, wherein the real-time PCR detection unit is used to perform quantitative PCR detection on HPV-infected tissue after 5-fluorouracil intervention; The first recording unit is used to record the HPV DNA level change data obtained by the real-time PCR detection unit, and calibrate the HPV DNA level change data as the first monitoring parameter for recording.

5. The evaluation system for the treatment of HPV infection using 5-fluorouracil according to claim 1, characterized in that: The second monitoring module includes a reverse transcription PCR detection unit and a second recording unit, wherein the reverse transcription PCR detection unit is used to perform quantitative reverse transcription PCR detection on HPV-infected tissues after 5-fluorouracil intervention to monitor changes in HPV transcription activity; The second recording unit is used to record the HPV transcription activity change data obtained by the reverse transcription PCR detection unit, and mark the HPV transcription activity change data as a second monitoring parameter for recording.

6. The evaluation system for the treatment of HPV infection using 5-fluorouracil according to claim 1, characterized in that: After the first monitoring parameter and the second monitoring parameter are output, the first monitoring parameter and the second monitoring parameter are arranged according to a time sequence of occurrence; Bidirectionally offsetting the arranged first monitoring parameters and second monitoring parameters respectively to obtain a plurality of first monitoring intervals corresponding to the first monitoring parameters and a plurality of second monitoring intervals corresponding to the second monitoring parameters; Collecting the number of first monitoring parameters in each of the first monitoring intervals and marking them as first parameters to be screened, and collecting the number of second monitoring parameters in each of the second monitoring intervals and marking them as second parameters to be screened; Obtaining a screening threshold, and comparing the screening threshold with the first parameter to be screened and the second parameter to be screened, and recording a first monitoring interval under the first parameter to be screened that is greater than the screening threshold as a first standard interval, and recording a second monitoring interval under the second parameter to be screened that is greater than the screening threshold as a second standard interval; The first monitoring parameter within the first standard interval and the second monitoring parameter within the second standard interval are retained, and the first monitoring parameter outside the first standard interval and the second monitoring parameter outside the second standard interval are screened out.

7. The evaluation system for the treatment of HPV infection using 5-fluorouracil according to claim 1, characterized in that: The efficacy evaluation module includes a comprehensive scoring unit and a dosage optimization unit, wherein the comprehensive scoring unit is provided with a comprehensive evaluation function, and the comprehensive evaluation function is used to calculate a comprehensive score of the treatment effect of HPV infection by comprehensively combining the first monitoring parameter and the second monitoring parameter, as well as the weight coefficient of the first monitoring parameter and the second monitoring parameter; The dose optimization unit is used to collect the intervention dose of 5-fluorouracil of biological samples with the same infection degree under each of the comprehensive scores, and determine the correlation formula between the intervention dose and the comprehensive score, and then determine the optimal dose of 5-fluorouracil intervention based on the correlation formula.

8. The evaluation system for the treatment of HPV infection using 5-fluorouracil according to claim 1, characterized in that: It also includes an early warning module, which is used to monitor the adverse reactions of biological samples during the 5-fluorouracil intervention process in real time and send out an early warning signal when an adverse reaction is detected; The early warning module includes a real-time monitoring unit and an early warning determination unit, wherein the real-time monitoring unit is used to monitor the blood concentration of 5-fluorouracil in the biological sample; The early warning determination unit analyzes the blood drug concentration according to a preset allowable fluctuation range, and when it is detected that the blood drug concentration exceeds the allowable fluctuation range, the early warning mechanism is triggered to send out an early warning signal.

9. A method for evaluating the use of 5-fluorouracil in the treatment of HPV infection, characterized in that: An evaluation system for using 5-fluorouracil to intervene in the treatment of HPV infection as described in any one of claims 1 to 8, comprising: Collecting biological samples from HPV-infected persons, wherein the biological samples include blood, saliva, and cervical secretions; Collect the viral load of the biological sample and the HPV DNA content in the biological sample, and determine the infection degree of the biological sample based on the viral load and the HPV DNA content; Monitor the changes in DNA levels in HPV-infected tissues under 5-fluorouracil intervention and record them as the first monitoring parameter; Monitor the changes in HPV transcription activity under the intervention of 5-fluorouracil and record it as the second monitoring parameter; The first monitoring parameter and the second monitoring parameter are combined to evaluate the therapeutic effect of 5-fluorouracil in intervening HPV infection, and a comprehensive score is output simultaneously, and then the optimal dose of 5-fluorouracil is determined based on the comprehensive score.

10. An electronic device, characterized in that: The electronic device comprises: at least one processor; and a memory communicatively coupled to the at least one processor; Wherein, the memory stores a computer program executable by the at least one processor, and the computer program is executed by the at least one processor so that the at least one processor can execute the evaluation system for using 5-fluorouracil to intervene in the treatment of HPV infection as described in any one of claims 1 to 8.

Images